ATLASKalaris Therapeutics (KLRS) earnings date: Nov 11, 2026
Kalaris Therapeutics (KLRS) reports earnings for the quarter ended Sep 30, 2026 on Wed, Nov 11, 2026. Analysts expect EPS of -$0.51.
Source: company filings and exchange data · Updated Nov 2, 2026
ATLAS view on KLRS
| Last price | $2.03 (-4.7%) |
|---|---|
| Normal 1-day range (±1σ) | ±4.6% |
| Earnings beat history | Beat the EPS estimate in 4 of the last 5 reports |
These figures come from the same calibrated model and valuation as the Kalaris Therapeutics stock page. They describe an ordinary period, not the earnings reaction itself, which is usually wider and can go either way.
Kalaris Therapeutics reports on Nov 11, 2026. One email the day before, with ATLAS’s read on Kalaris Therapeutics. You can switch it off at any time.
Alert me before KLRS reportsFree to start. Creating an account takes under a minute.
KLRS earnings at a glance
| Next report (confirmed) | Wed, Nov 11, 2026 |
|---|---|
| Time | Not stated |
| Period | Quarter ended Sep 30, 2026 |
| EPS estimate | -$0.51 |
| Last report | Aug 11, 2026 · Beat |
| Beat rate (last 5 reports) | 4 of 5 (80%) |
| Average EPS surprise | +9.0% |
| Average move around a report | ±4.5% (last 5) |
| Sector | Healthcare · Biotechnology |
Kalaris Therapeutics earnings history: last 5 reports
Kalaris Therapeutics last reported on Aug 11, 2026: EPS of -$0.48 against an estimate of -$0.49 (+2.0% surprise), a beat.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Aug 11, 2026 | -$0.49 | -$0.48 | +2.0% | Beat | 0.0% |
| May 12, 2026 | -$0.52 | -$0.46 | +11.5% | Beat | +2.1% |
| Mar 17, 2026 | -$0.55 | -$0.44 | +20.0% | Beat | -14.5% |
| Jan 23, 2026 | $1.61 | $1.87 | +16.2% | Beat | +0.7% |
| Nov 12, 2025 | -$0.61 | -$0.64 | -4.9% | Miss | +5.1% |
*Move: change in the closing price from the last close before the report day to the close the day after it, so it captures the reaction whether the company reported before the open or after the close.
Get the full ATLAS analysis for KLRS
See the fair value, the probability range and the earnings history of Kalaris Therapeutics on its ATLAS page.
Kalaris Therapeutics (KLRS) stock analysisPlans from €3.99 a month.
Kalaris Therapeutics earnings: frequently asked questions
When does Kalaris Therapeutics (KLRS) report earnings?
Kalaris Therapeutics is scheduled to report on Wednesday, November 11, 2026 (the time of day has not been stated). ATLAS only shows a confirmed date when the company or the exchange data provides one; check the investor relations page for the call details.
What is the EPS estimate for KLRS?
The consensus EPS estimate for the quarter ended Sep 30, 2026 is -$0.51 per share (USD). Estimates can change before the report.
How often does KLRS beat earnings estimates?
Of its last 5 reports with a recorded result, Kalaris Therapeutics beat the EPS estimate 4 times; the average surprise was +9.0%. Past results do not predict the next one.
How much does KLRS move around earnings?
Over its last 5 reports the stock moved an average of 4.5% (absolute, from the close before the report day to the close after it), and finished higher 3 of 5 times.
Did Kalaris Therapeutics beat earnings estimates last quarter?
Kalaris Therapeutics last reported on Aug 11, 2026: EPS of -$0.48 against an estimate of -$0.49 (+2.0% surprise), a beat.
How much does KLRS usually move in a day?
On a normal trading day the ATLAS model puts KLRS’s one-day range at about ±4.6%, with a 49% chance of closing higher. This is not an options-implied earnings move; earnings days are usually wider.
Also reporting on Wed, Nov 11, 2026
Educational information, not investment advice. Disclaimer